Results 31 to 40 of about 126,042 (242)

Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

open access: yesJournal of Translational Medicine, 2023
Background Cancer/testis antigens (CTAs) participate in the regulation of malignant biological behaviors in breast cancer. However, the function and mechanism of KK-LC-1, a member of the CTA family, in breast cancer are still unclear.
Xudong Zhu   +3 more
doaj   +1 more source

Acinic cell carcinoma of the breast: A comprehensive review

open access: yesBreast, 2022
Acinic cell carcinoma of the breast is a rare special subtype of breast cancer in the category of salivary gland-type tumors. It is morphologically similar to acinic cell carcinomas of salivary glands and pancreas and has a triple-negative phenotype ...
Azra Ajkunic   +6 more
doaj   +1 more source

Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high‐risk breast cancer

open access: yesMolecular Genetics & Genomic Medicine, 2019
Background Breast cancer is the most common cancer among women worldwide. Here, we report the prevalence of BRCA1/2 mutations in patients with high‐risk breast cancer from Inner Mongolia and Jilin, China, which was a part of a nationwide project on the ...
Xiaozhen Wang   +20 more
doaj   +1 more source

Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan.

open access: yesPLoS ONE, 2011
Discrepancies in the prognosis of triple negative breast cancer exist between Caucasian and Asian populations. Yet, the gene signature of triple negative breast cancer specifically for Asians has not become available. Therefore, the purpose of this study
Lee H Chen   +9 more
doaj   +1 more source

PPARα-Selective Antagonist GW6471 Inhibits Cell Growth in Breast Cancer Stem Cells Inducing Energy Imbalance and Metabolic Stress

open access: yesBiomedicines, 2021
Breast cancer is the most frequent cancer and the second leading cause of death among women. Triple-negative breast cancer is the most aggressive subtype of breast cancer and is characterized by the absence of hormone receptors and human epithelial ...
Vanessa Castelli   +10 more
doaj   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

open access: yesMolecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués   +3 more
wiley   +1 more source

Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray

open access: yesTumor Biology, 2017
Breast cancer has attracted substantial attention as one of the major cancers causing death in women. It is crucial to find potential biomarkers of prognostic value in breast cancer. In this study, the expression pattern of anterior gradient protein 2 in
Jilong Guo, Guohua Gong, Bin Zhang
doaj   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

open access: yesMolecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck   +12 more
wiley   +1 more source

Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. [PDF]

open access: yesPLoS ONE, 2012
A major challenge in breast cancer therapy is the lack of an effective therapeutic option for a particularly aggressive subtype of breast cancer, triple-negative breast cancer.
Yanfeng Qi   +6 more
doaj   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

open access: yesMolecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad   +35 more
wiley   +1 more source

Home - About - Disclaimer - Privacy